IMM Immupharma Plc

 

TIDMIMM 
 
 
Immupharma PLC 
03 December 2009 
 
? 
+------------------------------------+-------------------------------------------------+ 
| For Immediate Release              |                                 3 DECEMBER 2009 | 
+------------------------------------+-------------------------------------------------+ 
 
 
ImmuPharma PLC 
 
 
("ImmuPharma") 
 
 
R&D Symposium at the CNRS in Paris 
Analyst Visit 
 
 
ImmuPharma PLC (LSE: IMM) the specialist discovery and development 
pharmaceutical company, will today hold a R&D Symposium in Paris for analysts to 
discuss its cancer drug IPP-204106. The presentation will be given by both 
ImmuPharma's management team and key scientists from the Centre National de la 
Recherche Scientifique (CNRS), France's leading scientific research 
institution. 
 
 
IP-204106 is ImmuPharma's lead compound for cancer. The rights for this compound 
have been obtained through the Company's ongoing research collaboration with the 
CNRS. The molecule is a nucleolin antagonist and has a dual mechanism of action, 
acting both in preventing angiogenesis as well as proliferation. Preclinical 
data has shown that nucleolin antagonists inhibit the growth of tumours and 
metastasis in many cancer types. Having confirmed EUR1.15m of French government 
grants, ImmuPharma progressed clinical development plans of IPP-204106 during 
2009 and are likely to initiate a Phase I trial in early 2010 in cancer 
patients. 
 
 
No other new material information will be disclosed on the visit. The 
presentation will be available from Buchanan Communications. 
 
 
- Ends - 
 
 
For further information please contact: 
 
 
+----------------------------------------------------+---------------------------------+ 
| ImmuPharma PLC                                     |                +44 20 7152 4080 | 
+----------------------------------------------------+---------------------------------+ 
| Dimitri Dimitriou, Chief Executive Officer         |                                 | 
| Richard Warr, Chairman                             |                                 | 
+----------------------------------------------------+---------------------------------+ 
|                                                    |                                 | 
+----------------------------------------------------+---------------------------------+ 
| Buchanan Communications                            |                +44 20 7466 5000 | 
+----------------------------------------------------+---------------------------------+ 
| Lisa Baderoon                                      |                                 | 
+----------------------------------------------------+---------------------------------+ 
|                                                    |                                 | 
+----------------------------------------------------+---------------------------------+ 
| Panmure Gordon & Co (NOMAD and Broker)             |                +44 151 243 0963 | 
| Andrew Burnett                                     |                                 | 
| Rakesh Sharma                                      |                                 | 
+----------------------------------------------------+---------------------------------+ 
|                                                    |                                 | 
+----------------------------------------------------+---------------------------------+ 
| Noble & Company Limited                            |                +44 20 7763 2200 | 
+----------------------------------------------------+---------------------------------+ 
| James Bromhead                                     |                                 | 
| Sam Reynolds                                       |                                 | 
+----------------------------------------------------+---------------------------------+ 
 
 
Notes to Editors 
 
 
About ImmuPharma PLC 
 
 
ImmuPharma is a drug discovery and development group with its key operations in 
London and subsidiaries in Mulhouse,  France and Basle, Switzerland. The Company 
aims to develop novel drugs to treat serious medical conditions for which there 
is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) 
Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) 
Inflammatory and Allergic disorders. 
 
 
Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, 
life-threatening autoimmune disease, was licensed to Cephalon, Inc in a 
transaction worth up to $500m in milestone payments in addition to significant 
royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m 
post year end in Q1 2009 
The company also has a strong proprietary and collaborative drug development 
pipeline. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAUUGGCPUPBGQP 
 

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024